BetterLife Pharma (BETRF) Net Equity Issued and Repurchased (2011 - 2026)

BetterLife Pharma's Net Equity Issued and Repurchased history runs 10 years deep, the most recent figure standing at $188437.2 for Q2 2026.

• In Q2 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $188437.2; the TTM figure through Apr 2026 stood at $565217.8 (changed N/A YoY), while the FY2023 annual figure was $495230.2, down 94.58% from the prior year.
• Net Equity Issued and Repurchased for Q2 2026 stood at $188437.2, down from $211955.7 in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $1.2 million in Q2 2023, with the low at $112.19 in Q1 2022.
• The 3-year median for Net Equity Issued and Repurchased is $188437.2 (2026), against an average of $298151.9.
• Peak annual rise in Net Equity Issued and Repurchased reached 201859.87% in 2023, while the deepest fall reached 81.16% in 2023.
• BetterLife Pharma's Net Equity Issued and Repurchased stood at $117001.5 in 2022, then surged by 81.16% to $211955.7 in 2023, then slipped by 11.1% to $188437.2 in 2026.
• Business Quant data shows BETRF's Net Equity Issued and Repurchased at $188437.2 in Q2 2026, $211955.7 in Q4 2023, and $164824.8 in Q3 2023.